Optimizing the exchange of information in clinical trials

05.10.2012 11:56

IntraLinks, the leading global provider of content management and collaboration solutions for the cross-company exchange of sensitive business information, announced at the end of September that the biopharmaceutical group Actelion Pharmaceuticals Ltd in Allschwil/Basel (Switzerland) is using the IntraLinks Connect software solution to optimize its document exchange in the used in clinical studies. Actelion is engaged in the research, development and marketing of innovative treatments to close gaps in medical care.

Before introducing the IntraLinks solution, Actelion relied on traditional courier services to ensure confidential clinical documentation between sponsors and stakeholders. This resulted in very high shipping costs and a lot of manual effort for tracking and many other activities.

In order to optimize its documentation processes and thus achieve greater efficiency for both its own company and its investors, Actelion decided to use IntraLinks Connect. Based on the software solution, central portals for clinical studies are set up, which facilitate the significantly secure, compliant and auditable exchange of documents when analyzing the suitability of the site as well as at the start of the study, the implementation and the completion of the clinical study.

According to Acetelion, the high level of security, detailed reporting, workflows and analysis functions of IntraLinks Connect, combined with the qualified, professional support from the IntraLinks service team, were decisive arguments for choosing IntraLinks. “The hands-on work with IntraLinks has shown us not only the high level of development of the technology, but also the team's commitment to helping Actelion expand this development,” said Christine Schwenninger, Head of Global Clinical Monitoring at Actelion. “We look forward to working closely with IntraLinks in the coming years.”